Investors / Sweden / Sound Bioventures
Sound Bioventures
Venture capital · Malmö, Sweden · Europe
Sound Bioventures is a venture capital fund that invests in private companies in Europe and the USA developing novel medicines for unmet medical needs. It focuses on companies about to enter or already in the clinical stage, and typically takes board seats and reserves capital for future raises.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsclinical stagenovel medicineslife sciences
Your fit with Sound Bioventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsSound Bioventures lists 15 checked portfolio companies on its own site and is named in 7 funding rounds, 2 of them as lead. Its most frequent entry is Series A, 57% of the companies with a known first round. Its largest themes are Healthcare & Biotech (77%), AI & Machine Learning (12%) and Legal & Compliance (6%). 30% of its companies are based in United States. It invests most often alongside Industrifonden, Columbus Venture Partners and Criteria Bio Ventures.
Counts come from funding rounds that name Sound Bioventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Sound Bioventures' whole history. Rounds on record name 7 companies; its own site lists 15. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundSound Bioventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 57% |
| Series B | 43% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 1 |
| '26 | 3 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 39th | 15 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 95th | 27% of companies confirmed by a round |
| Sector focus | 93th | 77% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Industrifonden | 3 |
| Columbus Venture Partners | 2 |
| Criteria Bio Ventures | 2 |
| Modi Ventures | 2 |
| Pappas Capital | 2 |
| 3B Future Health Fund | 1 |
| 4BIO Capital | 1 |
| Abingworth | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers15100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 77% | 15% |
| AI & Machine Learning | 12% | 18% |
| Legal & Compliance | 6% | 2% |
| Cybersecurity | 6% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare Sound Bioventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
from public registers and its siteRecent portfolio activity
when companies last raised with Sound Bioventures| Date | Company | Stage |
|---|---|---|
| 14 Oct 2026 | Series A Led | |
| 29 Sept 2026 | Series A | |
| 5 May 2026 | Series A | |
| 12 Nov 2025 | Series B | |
| 3 Nov 2025 | Series A Led | |
| 17 Sept 2025 | Series B | |
| 17 Jul 2025 | Series B |
Round details for Sound Bioventures
Amounts, full round histories and every co-investor in Sound Bioventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
15 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aboleris Pharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and organ transplantation rejection. | Healthcare & Biotech | Portfolio page | ||
| Altay Therapeutics develops small molecules to address serious diseases by inhibiting transcription factors | Healthcare & Biotech | Oct 2026Series A | Page + round | |
| AnaCardio is developing novel drugs to treat heart failure | Healthcare & Biotech | Portfolio page | ||
| Artax Biopharma develops treatments for autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
| Arthex Biotech develops RNA medicine for diseases with unmet medical needs, including Myotonic Dystrophy. | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| BOOST Pharma develops a therapy for severe osteogenesis imperfecta, a brittle bone disease in children. | Healthcare & Biotech | Portfolio page | ||
| The company develops a therapy for severe osteogenesis imperfecta, a brittle bone disease | Healthcare & Biotech | Nov 2025Series A | Funding round | |
| Breye Therapeutics develops novel, orally administered ophthalmology drugs to meet the needs of patients at risk of vision loss. | Healthcare & Biotech | Sept 2026Series A | Page + round | |
| Cytospire Therapeutics develops next generation immune cell engagers, including multispecific antibodies and gamma delta T cell engagers, for cancer therapies. | Healthcare & Biotech | May 2026Series A | Page + round | |
| GC AI provides an artificial intelligence platform for in-house legal teams to review contracts and automate legal tasks. | Legal & ComplianceAI & Machine Learning | Nov 2025Series B | Funding round | |
| NephroDI Therapeutics is a pharmaceutical company developing a treatment for Nephrogenic Diabetes Insipidus (NDI), a rare genetic condition affecting children. | Healthcare & Biotech | Portfolio page | ||
| Teitur Trophics develops novel neuroprotective peptides for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Theolytics is developing systemically deliverable immunotherapies based on oncolytic adenoviruses to target solid tumours. | Healthcare & Biotech | Portfolio page | ||
| VarmX develops a universal bypassing agent to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants | Healthcare & Biotech | Portfolio page | ||
| XMTP Labs builds technology for secure communication and control of AI agents. | CybersecurityAI & Machine Learning | Jul 2025Series B | Funding round |
About this data
site last read 5 Nov 2026- Site
- soundbioventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 17 Jul 2025
- Companies checked
- 15
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Sound Bioventures' profile as data
Pull Sound Bioventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/soundbioventures.com
# also
GET /v1/firms/soundbioventures.com/portfolio
GET /v1/firms/soundbioventures.com/coinvestors
GET /v1/firms/soundbioventures.com/news